If Novartis's Gilenia Clears Safety Hurdle, Other Oral MS Drugs May Have An Easier Path

While fingolimod has a broadly similar safety profile to Merck Serono's cladribine and Teva's laquinimod, additional cardiac, pulmonary and ophthalmic adverse events may give Novartis's first mover a higher barrier to clear.